NewslettersDermal Cell News Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase III Trial of Roflumilast Cream in Atopic Dermatitis By lbeveridge - August 4, 2022 0 Arcutis Biotherapeutics, Inc. announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase III trial of roflumilast cream 0.15% in adults and children with atopic dermatitis. [Arcutis Biotherapeutics, Inc.] Press Release